Printed from https://ideas.repec.org/s/spr/pharme4.html
Content
October 2019, Volume 37, Issue 10
- 1219-1239 Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review
by Xiao Zang & Emanuel Krebs & Linwei Wang & Brandon D. L. Marshall & Reuben Granich & Bruce R. Schackman & Julio S. G. Montaner & Bohdan Nosyk - 1241-1260 Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review
by Dalia M. Dawoud & Alexander Haines & David Wonderling & Joanna Ashe & Jennifer Hill & Mihir Varia & Philip Dyer & Julian Bion - 1261-1276 Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations
by Jesse Elliott & Sasha Katwyk & Bláthnaid McCoy & Tammy Clifford & Beth K. Potter & Becky Skidmore & George A. Wells & Doug Coyle - 1277-1286 Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand
by Khachen Kongpakwattana & Zanfina Ademi & Thanaputt Chaiyasothi & Surakit Nathisuwan & Ella Zomer & Danny Liew & Nathorn Chaiyakunapruk - 1287-1300 Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013
by Elizabeth D. Brouwer & Anirban Basu & Kai Yeung - 1301-1302 Comment on: ‘The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study’
by Livio Garattini & Anna Padula
September 2019, Volume 37, Issue 9
- 1073-1080 Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Shijie Ren & Hazel Squires & Emma Hock & Eva Kaltenthaler & Andrew Rawdin & Constantine Alifrangis - 1081-1091 The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Edward Cox & Ros Wade & Mathilde Peron & Kristina Charlotte Dietz & Alison Eastwood & Stephen Palmer & Susan Griffin - 1093-1127 Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
by Marina Treskova & Stefan M. Scholz & Alexander Kuhlmann - 1129-1138 Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
by Mario J. N. M. Ouwens & Pralay Mukhopadhyay & Yiduo Zhang & Min Huang & Nicholas Latimer & Andrew Briggs - 1139-1153 Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample
by Christine Mpundu-Kaambwa & Gang Chen & Elisabeth Huynh & Remo Russo & Julie Ratcliffe - 1155-1163 Severity-Adjusted Probability of Being Cost Effective
by Matthijs M. Versteegh & Isaac Corro Ramos & Nasuh C. Buyukkaramikli & Amir Ansaripour & Vivian T. Reckers-Droog & Werner B. F. Brouwer - 1165-1176 Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe
by Dominik Golicki & Michał Jakubczyk & Katarzyna Graczyk & Maciej Niewada - 1177-1193 Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
by Thomas E. Delea & Xinke Zhang & Jordan Amdahl & Diana Boyko & Franziska Dirnberger & Marco Campioni & Ze Cong
August 2019, Volume 37, Issue 8
- 975-984 Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma
by Frederick W. Thielen & Nasuh C. Büyükkaramikli & Rob Riemsma & Debra Fayter & Nigel Armstrong & Ching-Yun Wei & Vanesa Huertas Carrera & Kate Misso & Gill Worthy & Jos Kleijnen & Isaac Corro Ramos - 985-993 Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal
by Becky Pennington & Shije Ren & Samantha Barton & Mariana Bacelar & Steven J. Edwards - 995-1010 Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
by Nikolaos Maniadakis & Evgenia Konstantakopoulou - 1011-1027 Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review
by Stuart J. Wright & William G. Newman & Katherine Payne - 1029-1039 The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective
by Simon Frey & Tom Stargardt & Udo Schneider & Jonas Schreyögg - 1041-1047 A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
by Kim Cocks & Marta Contente & Sarah Simpson & Michael DeRosa & Fiona C. Taylor & James W. Shaw - 1049-1064 Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions
by Mutsa Gumbie & Bonny Parkinson & Henry Cutler & Natalie Gauld & Virginia Mumford - 1065-1067 Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
by Katrine Wallace & Sandra Goble & Jeff Isaacson & Lara Maloney & Terri Cameron & Josh Bedel - 1069-1069 Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)
by Hui Shao & Vivian Fonseca & Charles Stoecker & Shuqian Liu & Lizheng Shi - 1071-1071 Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
by Mark Bounthavong & Javed Butler & Chantal M. Dolan & Jeffrey D. Dunn & Kathryn A. Fisher & Nina Oestreicher & Bertram Pitt & Paul J. Hauptman & David L. Veenstra
July 2019, Volume 37, Issue 7
- 871-877 The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis
by Eric Jutkowitz & Fernando Alarid-Escudero & Karen M. Kuntz & Hawre Jalal - 879-886 Autologous Chondrocyte Implantation with Chondrosphere for Treating Articular Cartilage Defects in the Knee: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Xavier Armoiry & Ewen Cummins & Martin Connock & Andrew Metcalfe & Pamela Royle & Rhona Johnston & Jeremy Rodrigues & Norman Waugh & Hema Mistry - 887-894 Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Rob Riemsma & Sabine Grimm & Debra Fayter & Sohan Deshpande & Nigel Armstrong & Willem Witlox & Xavier Pouwels & Steven Duffy & Gill Worthy & Jos Kleijnen & Manuela A. Joore - 895-919 A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective
by Steve Ryder & Kathleen Fox & Pratik Rane & Nigel Armstrong & Ching-Yun Wei & Sohan Deshpande & Lisa Stirk & Yi Qian & Jos Kleijnen - 921-929 Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation
by Hui Shao & Shuang Yang & Vivian Fonseca & Charles Stoecker & Lizheng Shi - 931-941 Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients
by Michelle Tew & Philip Clarke & Karin Thursky & Kim Dalziel - 943-952 Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease
by Yawen Jiang & Weiyi Ni - 953-962 The Cancer Drugs Fund in Practice and Under the New Framework
by Celia Sabry-Grant & Kinga Malottki & Alexander Diamantopoulos - 963-964 Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
by R. Brett McQueen & Melanie D. Whittington & Rick H. Chapman & Varun M. Kumar & Jonathan D. Campbell - 965-967 Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
by Holly Guy & Lydia Walder & Mark Fisher - 969-969 Correction to: Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities?
by Paul Mark Mitchell & Sridhar Venkatapuram & Jeff Richardson & Angelo Iezzi & Joanna Coast - 971-971 Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
by Baptiste Leurent & Manuel Gomes & Rita Faria & Stephen Morris & Richard Grieve & James R. Carpenter - 973-973 Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities
by Edna Keeney & Dalia Dawoud & Sofia Dias
June 2019, Volume 37, Issue 6
- 743-744 Cost-Effectiveness Analysis in the Context of US Commercial Health Insurance
by Bryan Dowd & John A. Nyman - 745-752 Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges
by David Thesmar & David Sraer & Lisa Pinheiro & Nick Dadson & Razvan Veliche & Paul Greenberg - 753-762 Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Joanna Picot & Neelam Kalita & Wendy Gaisford & Petra Harris & Oluchukwu Onyimadu & Keith Cooper - 763-775 Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sarah Davis & Rachid Rafia & Christopher Carroll & Jean Hamilton & Munira Essat - 777-818 Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
by Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi - 819-827 Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial
by Fuxiao Li & Xiang Li & Chuanhai Guo & Ruiping Xu & Fenglei Li & Yaqi Pan & Mengfei Liu & Zhen Liu & Chao Shi & Hui Wang & Minmin Wang & Hongrui Tian & Fangfang Liu & Ying Liu & Jingjing Li & Hong Cai & Li Yang & Zhonghu He & Yang Ke - 829-843 A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis
by Devin Incerti & Jeffrey R. Curtis & Jason Shafrin & Darius N. Lakdawalla & Jeroen P. Jansen - 845-865 Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden
by Santiago Zuluaga-Sanchez & Megan Teynor & Christopher Knight & Robin Thompson & Thomas Lundqvist & Mats Ekelund & Annabelle Forsmark & Adrian D. Vickers & Andrew Lloyd - 867-867 Correction to: The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study
by José Leal & Stefania Manetti & James Buchanan - 869-869 Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hema Mistry & Chidozie Nduka & Martin Connock & Jill Colquitt & Theodoros Mantopoulos & Emma Loveman & Renata Walewska & James Mason
May 2019, Volume 37, Issue 5
- 627-630 Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
by James F. O’Mahony - 631-643 An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis
by Matthew Franklin & James Lomas & Simon Walker & Tracey Young - 645-654 Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Lindsay Claxton & Joanne O’Connor & Nerys Woolacott & Kath Wright & Robert Hodgson - 655-667 Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Nigel Armstrong & Bram L. T. Ramaekers & Xavier Pouwels & Shona Lang & Svenja Petersohn & Rob Riemsma & Gillian Worthy & Lisa Stirk & Janine Ross & Jos Kleijnen & Manuela A. Joore - 669-688 Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review
by Natalia Ruiz-Negrón & Jyothi Menon & Jordan B. King & Junjie Ma & Brandon K. Bellows - 689-699 Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial
by Aureliano Paolo Finch & Patricia van Velzen & Gerben ter Riet & Peter J. Sterk & Jan M. Prins & Judith E. Bosmans - 701-714 Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States
by Holly Guy & Vicki Laskier & Mark Fisher & W. Richey Neuman & Iwona Bucior & Steven Deitelzweig & Alexander T. Cohen - 715-725 EQ-5D-5L Valuation for the Malaysian Population
by Asrul Akmal Shafie & Annushiah Vasan Thakumar & Ching Jou Lim & Nan Luo & Kim Rand-Hendriksen & Faridah Aryani Md Yusof - 727-737 Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology
by Istvan M. Majer & Jean-Gabriel Castaigne & Stephen Palmer & Lucy DeCosta & Marco Campioni - 739-739 Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Lindsay Claxton & Joanne O’Connor & Nerys Woolacott & Kath Wright & Robert Hodgson - 741-741 Correction to: Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study
by Matthew Franklin & Sarah Davis & Michelle Horspool & Wei Sun Kua & Steven Julious
April 2019, Volume 37, Issue 4
- 447-450 Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness
by Lisa A. Prosser & Eve Wittenberg - 451-456 The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra
by Werner B. F. Brouwer - 457-460 Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution
by Christopher McCabe - 461-473 Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time
by Scott D. Grosse & Jamison Pike & Rieza Soelaeman & J. Mick Tilford - 475-499 Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature
by Eve Wittenberg & Lyndon P. James & Lisa A. Prosser - 501-511 Using Discrete-Choice Experiment Methods to Estimate the Value of Informal Care: The Case of Children with Intellectual Disability
by Sheena Arora & Stephen Goodall & Rosalie Viney & Stewart Einfeld - 513-530 Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England
by Sandy Tubeuf & Eirini-Christina Saloniki & David Cottrell - 531-540 The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment
by Renske J. Hoefman & Job Exel & Werner B. F. Brouwer - 541-551 Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders
by Tara A. Lavelle & Milton C. Weinstein & Joseph P. Newhouse & Kerim Munir & Karen A. Kuhlthau & Lisa A. Prosser - 553-562 Economic Spillover Effects of Intensive Unpaid Caregiving
by Josephine C. Jacobs & Courtney H. Van Houtven & Terri Tanielian & Rajeev Ramchand - 563-572 Dementia Family Caregivers’ Willingness to Pay for an In-home Program to Reduce Behavioral Symptoms and Caregiver Stress
by Eric Jutkowitz & Danny Scerpella & Laura T. Pizzi & Katherine Marx & Quincy Samus & Catherine Verrier Piersol & Laura N. Gitlin - 573-583 Close-Person Spill-Overs in End-of-Life Care: Using Hierarchical Mapping to Identify Whose Outcomes to Include in Economic Evaluations
by Alastair Canaway & Hareth Al-Janabi & Philip Kinghorn & Cara Bailey & Joanna Coast - 585-596 An Examination of Downstream Effects of Bereavement on Healthcare Utilization for Surviving Spouses in a National Sample of Older Adults
by Katherine A. Ornstein & Melissa M. Garrido & Albert L. Siu & Evan Bollens-Lund & Omari-Khalid Rahman & Amy S. Kelley - 597-608 Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions
by Pei-Jung Lin & Brittany D’Cruz & Ashley A. Leech & Peter J. Neumann & Myrlene Sanon Aigbogun & Dorothee Oberdhan & Tara A. Lavelle - 609-620 Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D
by Clare C. Brown & J. Mick Tilford & Nalin Payakachat & D. Keith Williams & Karen A. Kuhlthau & Jeffrey M. Pyne & Renske J. Hoefman & Werner B. F. Brouwer - 621-623 The Inclusion of Spillover Effects in Economic Evaluation: A Public Health Economics Perspective
by Rhiannon Tudor Edwards - 625-625 Correction to: Parental Health Spillover in Cost‑Effectiveness Analysis: Evidence from Self‑Harming Adolescents in England
by Sandy Tubeuf & Eirini-Christina Saloniki & David Cottrell
March 2019, Volume 37, Issue 3
- 293-299 Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
by J. Jaime Caro & John E. Brazier & Jonathan Karnon & Peter Kolominsky-Rabas & Alistair J. McGuire & Erik Nord & Michael Schlander - 301-331 Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review
by Chun-Ru Chien & Daniel M. Geynisman & Bumyang Kim & Ying Xu & Ya-Chen Tina Shih - 333-343 Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Emma Simpson & Jean Hamilton & Daniel Pollard & Mark Clowes & Eva Kaltenthaler & David Meiklejohn & Nick Morley - 345-357 Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Tosin Lambe & Rui Duarte & James Mahon & Sarah Nevitt & Janette Greenhalgh & Angela Boland & Sophie Beale & Eleanor Kotas & Joanne McEntee & Ian Pomeroy - 359-389 Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review
by Gian Luca Di Tanna & Anna Bychenkova & Frank O’Neill & Heidi S. Wirtz & Paul Miller & Briain Ó Hartaigh & Gary Globe - 391-405 Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
by Holly Guy & Lydia Walder & Mark Fisher - 407-417 Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation
by Nicolas Krucien & Nathalie Pelletier-Fleury & Amiram Gafni - 419-433 Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and Neck
by Brent A. Metfessel & Michelle D. Mentel & Amy Phanel & Mary Ann Dimartino & Mureen Allen & Samuel Ho - 435-446 Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis
by Emma Warren & Kristen Morgan & Toby J. Toward & Matthias Schwenkglenks & Joanna Leadbetter
February 2019, Volume 37, Issue 2
- 119-130 Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
by Linda M. Vries & Pieter H. M. Baal & Werner B. F. Brouwer - 131-139 Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Ros Wade & Alessandro Grosso & Emily South & Claire Rothery & Pedro Saramago & Laetitia Schmitt & Kath Wright & Stephen Palmer - 141-153 Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nasuh C. Büyükkaramikli & Saskia Groot & Rob Riemsma & Debra Fayter & Nigel Armstrong & Piet Portegijs & Steven Duffy & Jos Kleijnen & Maiwenn J. Al - 155-167 The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence
by Richard Perry & George Braileanu & Thomas Palmer & Paul Stevens - 169-200 Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review
by Edward T. Chiyaka & Van T. Nghiem & Lu Zhang & Abhishek Deshpande & Patricia Dolan Mullen & Phuc Le - 201-226 Discrete Choice Experiments in Health Economics: Past, Present and Future
by Vikas Soekhai & Esther W. Bekker-Grob & Alan R. Ellis & Caroline M. Vass - 227-238 Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis
by Tracey-Lea Laba & Helen K. Reddel & Nicholas J. Zwar & Guy B. Marks & Elizabeth Roughead & Anthony Flynn & Michele Goldman & Aine Heaney & Kirsty Lembke & Stephen Jan - 239-253 Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
by Eytan Stein & Jipan Xie & Emilie Duchesneau & Subrata Bhattacharyya & Umakanth Vudumula & Briana Ndife & Gaetano Bonifacio & Annie Guerin & Nanxin Li & George Joseph - 255-266 Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data
by Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini - 267-278 Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand
by Bunchai Chongmelaxme & Pochamana Phisalprapa & Ratree Sawangjit & Piyameth Dilokthornsakul & Nathorn Chaiyakunapruk - 279-289 Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding
by Thananan Rattanachotphanit & Chulaporn Limwattananon & Onanong Waleekhachonloet & Phumtham Limwattananon & Kittisak Sawanyawisuth - 291-291 Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand
by Bunchai Chongmelaxme & Pochamana Phisalprapa & Ratree Manthaisong & Piyameth Dilokthornsakul & Nathorn Chaiyakunapruk
January 2019, Volume 37, Issue 1
- 1-6 Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?
by Salah Ghabri & Matt Stevenson & Jörgen Möller & J. Jaime Caro - 7-18 Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Christopher Carroll & John Stevens & Emma Simpson & Praveen Thokala & Ruth Wong & Josh Wright & Rebecca Auer - 19-27 Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Daniel Gallacher & Xavier Armoiry & Peter Auguste & Rachel Court & Theodoros Mantopoulos & Jacoby Patterson & Maria Santis & Joanne Cresswell & Hema Mistry - 29-43 One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation
by Brendan Mulhern & Richard Norman & Deborah J. Street & Rosalie Viney - 45-61 Systematic Literature Review of the Economic Burden of Celiac Disease
by Elizabeth S. Mearns & Aliki Taylor & Talia Boulanger & Kelly J. Craig & Michele Gerber & Daniel A. Leffler & Jennifer Drahos & David S. Sanders & Benjamin Lebwohl - 63-74 Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany
by Katharina Kähm & Michael Laxy & Udo Schneider & Rolf Holle - 75-84 The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals
by Becky Pennington & Monica Hernandez-Alava & Stephen Pudney & Allan Wailoo - 85-92 Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study
by Namita Joshi & Marja Hensen & Sachin Patel & Weiwei Xu & Kathy Lasch & Elly Stolk - 93-103 Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool
by Maria Gheorghe & Renske J. Hoefman & Matthijs M. Versteegh & Job Exel - 105-116 Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
by Min Huang & M. Catherine Pietanza & Ayman Samkari & James Pellissier & Thomas Burke & Sheenu Chandwani & Fansen Kong & A. Simon Pickard - 117-117 Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
by James Love-Koh & Alison Peel & Juan Carlos Rejon-Parrilla & Kate Ennis & Rosemary Lovett & Andrea Manca & Anastasia Chalkidou & Hannah Wood & Matthew Taylor
December 2018, Volume 36, Issue 12
- 1395-1405 Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues
by Patricia M. Danzon - 1407-1420 Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
by Jorge Mestre-Ferrandiz & Néboa Zozaya & Bleric Alcalá & Álvaro Hidalgo-Vega - 1421-1426 Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models
by Anthony J. Hatswell & Ash Bullement & Andrew Briggs & Mike Paulden & Matthew D. Stevenson - 1427-1437 Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Iñigo Bermejo & Shijie Ren & Emma Simpson & Mark Clowes & David L. Scott & Adam Young & Matt Stevenson - 1439-1451 The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
by James Love-Koh & Alison Peel & Juan Carlos Rejon-Parrilla & Kate Ennis & Rosemary Lovett & Andrea Manca & Anastasia Chalkidou & Hannah Wood & Matthew Taylor - 1453-1462 Understanding and Identifying Key Issues with the Involvement of Clinicians in the Development of Decision-Analytic Model Structures: A Qualitative Study
by Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast - 1463-1473 Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
by Mark Bounthavong & Javed Butler & Chantal M. Dolan & Jeffrey D. Dunn & Kathryn A. Fisher & Nina Oestreicher & Bertram Pitt & Paul J. Hauptman & David L. Veenstra - 1475-1490 Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
by Yun-Kyung Kim & Joon Young Song & Hyeongap Jang & Tae Hyun Kim & Heejo Koo & Lijoy Varghese & Euna Han
November 2018, Volume 36, Issue 11
- 1299-1308 Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Micah Rose & Jonathan Shepherd & Petra Harris & Karen Pickett & Joanne Lord - 1309-1319 Model Structuring for Economic Evaluations of New Health Technologies
by Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon - 1321-1331 Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis
by Jean-Hugues Salmon & Anne-Christine Rat & Isabelle Charlot-Lambrecht & Jean-Paul Eschard & Damien Jolly & Bruno Fautrel - 1333-1343 Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
by Mahdi Gharaibeh & Ali McBride & David S. Alberts & Brian Erstad & Marion Slack & Nimer Alsaid & J. Lyle Bootman & Ivo Abraham - 1345-1353 Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L
by Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill - 1355-1365 Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients
by Kristina R. Dahlstrom & Shuangshuang Fu & Wenyaw Chan & Zeena Shelal & Lois M. Ramondetta & David R. Lairson - 1367-1376 Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case–Control Study in Japan
by Haruhisa Fukuda & Takahisa Yano & Nobuyuki Shimono - 1377-1389 Severity-Stratified Discrete Choice Experiment Designs for Health State Evaluations
by Sesil Lim & Marcel F. Jonker & Mark Oppe & Bas Donkers & Elly Stolk
October 2018, Volume 36, Issue 10
- 1135-1141 Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?
by John W. Stevens - 1143-1151 Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachid Rafia & Abdullah Pandor & Sarah Davis & John W. Stevens & Sue Harnan & Mark Clowes & Youssef Sorour & Robert Cutting - 1153-1163 Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Angela Stainthorpe & Janette Greenhalgh & Adrian Bagust & Marty Richardson & Angela Boland & Sophie Beale & Rui Duarte & Eleanor Kotas & Lindsay Banks & Daniel Palmer - 1165-1200 Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review
by Carlos E. Rodriguez-Martinez & Monica P. Sossa-Briceño & Jose A. Castro-Rodriguez - 1201-1222 Costs of Invasive Meningococcal Disease: A Global Systematic Review
by Bing Wang & Renee Santoreneos & Hossein Afzali & Lynne Giles & Helen Marshall - 1223-1252 Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations
by Luis Hernandez & Malinda O’Donnell & Maarten Postma - 1253-1261 Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis
by Jesse Elliott & Bláthnaid McCoy & Tammy Clifford & George A. Wells & Doug Coyle - 1263-1272 The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study
by José Leal & Stefania Manetti & James Buchanan - 1273-1284 Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
by Mahdi Gharaibeh & Ali McBride & David S. Alberts & Marion Slack & Brian Erstad & Nimer Alsaid & J. Lyle Bootman & Ivo Abraham - 1285-1296 Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany
by Afschin Gandjour & Dennis A. Ostwald - 1297-1297 Comment on: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
by Baptiste Leurent & Manuel Gomes & James Carpenter
September 2018, Volume 36, Issue 9
- 1031-1041 Are PCSK9 Inhibitors Cost Effective?
by Max J. Korman & Kjetil Retterstøl & Ivar Sønbø Kristiansen & Torbjørn Wisløff - 1043-1061 A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values
by Stavros Petrou & Joseph Kwon & Jason Madan - 1063-1072 Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Lesley Uttley & Iñigo Bermejo & Shijie Ren & Marrissa Martyn-St James & Ruth Wong & David L. Scott & Adam Young & Matt Stevenson - 1073-1081 Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal
by Xavier Armoiry & Martin Connock & Alexander Tsertsvadze & Ewen Cummins & G. J. Melendez-Torres & Pam Royle & Aileen Clarke - 1083-1092 Review of Economic Value Drivers of the Treatment of Overactive Bladder
by Sonya J. Snedecor - 1093-1099 Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
by T. Joseph Mattingly & Joseph F. Levy & Julia F. Slejko & Nneka C. Onwudiwe & Eleanor M. Perfetto - 1101-1112 Smoking Cessation: A Comparison of Two Model Structures
by Becky Pennington & Alex Filby & Lesley Owen & Matthew Taylor - 1113-1124 Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan
by Verin Lertjanyakun & Nathorn Chaiyakunapruk & Susumu Kunisawa & Yuichi Imanaka - 1125-1134 Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)
by Hui Shao & Vivian Fonseca & Charles Stoecker & Shuqian Liu & Lizheng Shi
August 2018, Volume 36, Issue 8
- 883-888 Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation
by Feng Xie - 889-901 Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
by Baptiste Leurent & Manuel Gomes & Rita Faria & Stephen Morris & Richard Grieve & James R. Carpenter - 903-915 Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Abdullah Pandor & Matt Stevenson & John Stevens & Marrissa Martyn-St James & Jean Hamilton & Jenny Byrne & Claudius Rudin & Andrew Rawdin & Ruth Wong - 917-927 Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Robert F. Wolff & Xavier Pouwels & Marije Oosterhoff & Anoukh Giessen & Gill Worthy & Caro Noake & Nigel Armstrong & Jos Kleijnen & Manuela A. Joore - 929-939 Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence
by Didik Setiawan & Abrham Wondimu & KohJun Ong & Albert Jan Hoek & Maarten J. Postma - 941-955 Does Non-Adherence Increase Treatment Costs in Schizophrenia?
by Mark Pennington & Paul McCrone - 957-971 Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
by R. Brett McQueen & Danielle N. Sheehan & Melanie D. Whittington & Job F. M. Boven & Jonathan D. Campbell - 973-986 Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment
by Juan Marcos González & Justin Doan & David J. Gebben & Marco Boeri & Mayer Fishman - 987-994 Applying GRADE Criteria to Clinical Inputs to Cost-Effectiveness Modeling Studies
by Alexander Mensch & Tanja Beck & Daniele Civello & Christopher Kunigkeit & Nicole Lachmann & Stephanie Stock & Afschin Gandjour & Dirk Müller - 995-1004 Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China
by Yuqing Tang & Chaojie Liu & Junjie Liu & Xinping Zhang & Keyuan Zuo - 1005-1013 Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors
by Chan Shen & Arvind Dasari & Dian Gu & Yiyi Chu & Shouhao Zhou & Ying Xu & Daniel Halperin & Shuangshuang Fu & James C. Yao & Ya-Chen Tina Shih - 1015-1027 Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
by Paul Emery & Marjolijn Keep & Steve Beard & Chris Graham & LaStella Miles & Steffen Marc Jugl & Praveen Gunda & Anna Halliday & Helena Marzo-Ortega - 1029-1029 Comment on: “Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales Onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in Children”
by Emma Frew & Tosin Lambe
July 2018, Volume 36, Issue 7
- 731-732 Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries?
by Alan Haycox - 733-743 Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?
by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Carmelo A. Juárez-Castelló - 745-758 Discounting in Economic Evaluations
by Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton - 759-768 Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Matt Stevenson & Abdullah Pandor & Jean Hamilton & John Stevens & Clare Rowntree & Marrissa Martyn-St James & Andrew Rawdin & Ruth Wong - 769-778 Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Shijie Ren & Iñigo Bermejo & Emma Simpson & Ruth Wong & David L. Scott & Adam Young & Matt Stevenson - 779-807 The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
by Alex Diamantopoulos & Emily Wright & Katerina Vlahopoulou & Laura Cornic & Nils Schoof & Toby M. Maher - 809-822 Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
by Guy Neff & Woodie Zachry III - 823-835 The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests
by Alison F. Smith & Mike Messenger & Peter Hall & Claire Hulme - 837-851 Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
by Irina A. Tikhonova & Nicola Huxley & Tristan Snowsill & Louise Crathorne & Jo Varley-Campbell & Mark Napier & Martin Hoyle - 853-865 Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
by Przemysław Holko & Paweł Kawalec & Andrzej Pilc - 867-878 Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
by Vanessa Buchanan & Will Sullivan & Chris Graham & LaStella Miles & Steffen Marc Jugl & Praveen Gunda & Anna Halliday & Bruce Kirkham - 879-879 Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis”
by Ena Singh - 881-881 Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
by Guy Neff & Woodie Zachry
June 2018, Volume 36, Issue 6
- 637-640 3L, 5L, What the L? A NICE Conundrum
by Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk - 641-643 Once Bitten Twice Shy: Thinking Carefully Before Adopting the EQ-5D-5L
by Jeff Round - 645-661 A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D
by Ines Buchholz & Mathieu F. Janssen & Thomas Kohlmann & You-Shan Feng - 663-674 German Value Set for the EQ-5D-5L
by Kristina Ludwig & J.-Matthias Graf von der Schulenburg & Wolfgang Greiner - 675-697 Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries
by Mathieu F. Janssen & Gouke J. Bonsel & Nan Luo - 699-713 Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
by Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin - 715-725 Head-to-Head Comparison of EQ‐5D‐3L and EQ‐5D‐5L Health Values
by Anna Selivanova & Erik Buskens & Paul F. M. Krabbe - 727-727 Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
by Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin - 729-729 Correction to: 3L, 5L, What the L? A NICE Conundrum
by Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk
May 2018, Volume 36, Issue 5
- 509-522 Cost-Effectiveness Thresholds: the Past, the Present and the Future
by Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong - 523-532 Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities
by Edna Keeney & Dalia Dawoud & Sofia Dias - 533-543 Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Xavier G. L. V. Pouwels & Robert Wolff & Bram L. T. Ramaekers & Anoukh Giessen & Shona Lang & Steve Ryder & Gill Worthy & Steven Duffy & Nigel Armstrong & Jos Kleijnen & Manuela A. Joore - 545-553 Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Keith Cooper & Geoff Frampton & Petra Harris & Micah Rose & Maria Chorozoglou & Karen Pickett - 555-565 The Australian Managed Entry Scheme: Are We Getting it Right?
by Haitham W. Tuffaha & Paul A. Scuffham - 567-589 Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review
by Lucia Sara D’Angiolella & Paolo Angelo Cortesi & Alessandra Lafranconi & Mariangela Micale & Sveva Mangano & Giancarlo Cesana & Lorenzo Giovanni Mantovani - 591-601 Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
by Torbjørn Wisløff & Richard White & Olav Dalgard & Ellen J. Amundsen & Hinta Meijerink & Astrid Louise Løvlie & Hilde Kløvstad - 603-612 A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet
by Björn Stollenwerk & Sergio Iannazzo & Ron Akehurst & Michael Adena & Andrew Briggs & Bastian Dehmel & Patrick Parfrey & Vasily Belozeroff - 613-624 New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes
by Alice Varnava & Robert Bracchi & Karen Samuels & Dyfrig A. Hughes & Philip A. Routledge - 625-636 Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy
by M. Ruggeri & M. Basile & C. Drago & F. R. Rolli & A. Cicchetti
April 2018, Volume 36, Issue 4
- 385-386 Is ICER NICEr?
by Deborah Freund & Jennifer Choi - 387-398 Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Robert Hodgson & Matthew Walton & Mousumi Biswas & Teumzghi Mebrahtu & Nerys Woolacott - 399-406 Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hema Mistry & Chidozie Nduka & Martin Connock & Jill Colquitt & Theodoros Mantopoulos & Emma Loveman & Renata Walewska & James Mason - 407-417 The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)
by Salah Ghabri & Erwan Autin & Anne-Isabelle Poullié & Jean Michel Josselin - 419-434 A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
by Ewa Stawowczyk & Paweł Kawalec - 435-449 Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review
by Dolly Han & Nicolas Iragorri & Fiona Clement & Diane Lorenzetti & Eldon Spackman - 451-465 Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index–9 Dimension (CHU-9D) Score for Economic Evaluation in Children
by Tosin Lambe & Emma Frew & Natalie J. Ives & Rebecca L. Woolley & Carole Cummins & Elizabeth A. Brettell & Emma N. Barsoum & Nicholas J. A. Webb - 467-475 The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017
by Chris Skedgel & Dominika Wranik & Min Hu - 477-493 Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia
by Axel C. Mühlbacher & Andrew Sadler & Franz-Werner Dippel & Christin Juhnke - 495-504 Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
by Josh J. Carlson & Kangho Suh & Panos Orfanos & William Wong